Cargando…

Fulvestrant reverses doxorubicin resistance in multidrug-resistant breast cell lines independent of estrogen receptor expression

Drug resistance, a major obstacle to successful cancer chemotherapy, frequently occurs in recurrent or metastatic breast cancer and results in poor clinical response. Fulvestrant is a new type of selective estrogen receptor (ER) downregulator and a promising endocrine therapy for breast cancer. In t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Yuan, Jiang, Donghai, Sui, Meihua, Wang, Xiaojia, Fan, Weimin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2017
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5355712/ https://www.ncbi.nlm.nih.gov/pubmed/28000875 http://dx.doi.org/10.3892/or.2016.5315

Ejemplares similares

Elacestrant demonstrates strong anti-estrogenic activity in PDX models of estrogen-receptor positive endocrine-resistant and fulvestrant-resistant breast cancer
por: Pancholi, Sunil, et al.
Publicado: (2022)

Resveratrol reverses multidrug resistance in human breast cancer doxorubicin-resistant cells
por: HUANG, FANG, et al.
Publicado: (2014)

Identification of the Significant Genes Regulated by Estrogen Receptor in Estrogen Receptor-Positive Breast Cancer and Their Expression Pattern Changes When Tamoxifen or Fulvestrant Resistance Occurs
por: Cheng, Ran, et al.
Publicado: (2020)

Anti-tumor efficacy of fulvestrant in estrogen receptor positive gastric cancer
por: Yi, Jun Ho, et al.
Publicado: (2014)

Endoxifen and fulvestrant regulate estrogen-receptor α and related DEADbox proteins
por: Asberger, Jasmin, et al.
Publicado: (2020)

Real-world data of fulvestrant as first-line treatment of postmenopausal women with estrogen receptor-positive metastatic breast cancer
por: Blancas, I., et al.
Publicado: (2021)

Phase I Study of Intravenous PSC‐833 and Doxorubicin: Reversal of Multidrug Resistance
por: Minami, Hironobu, et al.
Publicado: (2001)

Fulvestrant-Mediated Inhibition of Estrogen Receptor Signaling Slows Lung Cancer Progression
por: Tang, Hexiao, et al.
Publicado: (2014)

Reversal of Multidrug Resistance by Apolipoprotein A1-Modified Doxorubicin Liposome for Breast Cancer Treatment
por: An, Duopeng, et al.
Publicado: (2021)

Reversal of doxorubicin-resistance by Salvia miltiorrhiza ligustrazine in the SHG44/doxorubicin glioma drug-resistant cell line
por: Wang, Feng, et al.
Publicado: (2017)

Economic Evaluation for Palbociclib Plus Fulvestrant vs Ribociclib Plus Fulvestrant and Abemaciclib Plus Fulvestrant in Endocrine-Resistant Advanced or Metastatic Breast Cancer in Italy
por: Colombo, Giorgio Lorenzo, et al.
Publicado: (2023)

Early multidrug resistance, defined by changes in intracellular doxorubicin distribution, independent of P-glycoprotein.
por: Schuurhuis, G. J., et al.
Publicado: (1991)

MDR1 Inhibition Reverses Doxorubicin-Resistance in Six Doxorubicin-Resistant Canine Prostate and Bladder Cancer Cell Lines
por: Packeiser, Eva-Maria, et al.
Publicado: (2023)

Celecoxib Prevents Doxorubicin-Induced Multidrug Resistance in Canine and Mouse Lymphoma Cell Lines
por: Karai, Edina, et al.
Publicado: (2020)

Estrogen Enhances the Expression of the Multidrug Transporter Gene ABCG2—Increasing Drug Resistance of Breast Cancer Cells through Estrogen Receptors
por: Chang, Fung-Wei, et al.
Publicado: (2017)

Reversal of multidrug resistance by surfactants.
por: Woodcock, D. M., et al.
Publicado: (1992)

Hollow MIL-125 Nanoparticles Loading Doxorubicin Prodrug and 3-Methyladenine for Reversal of Tumor Multidrug Resistance
por: Guo, Qingfeng, et al.
Publicado: (2023)

Chemotherapeutic efficacy of the protein-doxorubicin conjugates on multidrug resistant rat hepatoma cell line in vitro.
por: Ohkawa, K., et al.
Publicado: (1993)

Rethinking the combination treatment of fulvestrant and anastrozole for metastatic breast cancer: an integrated reanalysis of aromatase–estrogen receptor axis
por: Huang, Xing
Publicado: (2019)

Fulvestrant 500 mg vs 250 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer: a randomized, double-blind registrational trial in China
por: Zhang, Qingyuan, et al.
Publicado: (2016)

SNAI2 upregulation is associated with an aggressive phenotype in fulvestrant-resistant breast cancer cells and is an indicator of poor response to endocrine therapy in estrogen receptor-positive metastatic breast cancer
por: Alves, Carla L., et al.
Publicado: (2018)

Reversal effects of nomegestrol acetate on multidrug resistance in adriamycin-resistant MCF7 breast cancer cell line
por: Li, Jie, et al.
Publicado: (2001)

Effect of Berry Extracts and Bioactive Compounds on Fulvestrant (ICI 182,780) Sensitive and Resistant Cell Lines
por: Woode, Denzel R., et al.
Publicado: (2012)

Reversal of multidrug resistance in leukemia cells using a transferrin-modified nanomicelle encapsulating both doxorubicin and psoralen
por: Wang, He-Wen, et al.
Publicado: (2020)

Functional Doxorubicin-Loaded Omega-3 Unsaturated Fatty Acids Nanoparticles in Reversing Hepatocellular Carcinoma Multidrug Resistance
por: Wang, Chunlei, et al.
Publicado: (2021)

Cryptotanshinone Inhibits ERα-Dependent and -Independent BCRP Oligomer Formation to Reverse Multidrug Resistance in Breast Cancer
por: Ni, Wenting, et al.
Publicado: (2021)

Distinct mechanisms of resistance to fulvestrant treatment dictate level of ER independence and selective response to CDK inhibitors in metastatic breast cancer
por: Kaminska, Kamila, et al.
Publicado: (2021)

Promising Therapeutic Impact of a Selective Estrogen Receptor Downregulator, Fulvestrant, as Demonstrated In Vitro upon Low-Grade Serous Ovarian Carcinoma Cell Lines
por: Shanta, Kamrunnahar, et al.
Publicado: (2022)

Detection of Estrogen Receptor Alpha and Assessment of Fulvestrant Activity in MCF-7 Tumor Spheroids Using Microfluidics and SERS
por: Kapara, Anastasia, et al.
Publicado: (2021)

Curcumin reverses doxorubicin resistance via inhibition the efflux function of ABCB4 in doxorubicin-resistant breast cancer cells
por: Wen, Chunjie, et al.
Publicado: (2019)

Reversal of multidrug resistance by 5,5’-dimethoxylariciresinol-4-O-β-D-glucoside in doxorubicin-resistant human leukemia K562/DOX
por: Wang, Tian-Xiao, et al.
Publicado: (2013)

The estrogen receptor influences microtubule-associated protein tau (MAPT) expression and the selective estrogen receptor inhibitor fulvestrant downregulates MAPT and increases the sensitivity to taxane in breast cancer cells
por: Ikeda, Hirokuni, et al.
Publicado: (2010)

Conserved cell populations in doxorubicin-resistant human nasal natural killer/T cell lymphoma cell line: super multidrug resistant cells?
por: Zhang, Xudong, et al.
Publicado: (2018)

Phase IB study of doxorubicin in combination with the multidrug resistance reversing agent S9788 in advanced colorectal and renal cell cancer.
por: Punt, C. J., et al.
Publicado: (1997)

Doxorubicin-loading core-shell pectin nanocell: A novel nanovehicle for anticancer agent delivery with multidrug resistance reversal
por: Ouyang, Jiabi, et al.
Publicado: (2020)

Differential modulation of doxorubicin toxicity to multidrug and intrinsically drug resistant cell lines by anti-oestrogens and their major metabolites.
por: Kirk, J., et al.
Publicado: (1993)

Early Switch to Fulvestrant Plus Palbociclib Improves Outcomes in ESR1-Mutated, Estrogen Receptor-Positive Metastatic Breast Cancer
por: Jacobson, Anne
Publicado: (2022)

Mathematical Modeling Identifies Optimum Palbociclib-fulvestrant Dose Administration Schedules for the Treatment of Patients with Estrogen Receptor–positive Breast Cancer
por: Cheng, Yu-Chen, et al.
Publicado: (2023)

Reversal of Ovarian Cancer Cell Lines Multidrug Resistance Phenotype by the Association of Apiole with Chemotherapies
por: Afonso de Lima, Carolina, et al.
Publicado: (2020)

Chidamide Combined With Doxorubicin Induced p53-Driven Cell Cycle Arrest and Cell Apoptosis Reverse Multidrug Resistance of Breast Cancer
por: Cao, Lixia, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_1ci55p4hsljmqabf0r0vsotu7p